198 related articles for article (PubMed ID: 38674436)
1. Using the molecular classification of glioblastoma to inform personalized treatment.
Olar A; Aldape KD
J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
[TBL] [Abstract][Full Text] [Related]
2. Understanding glioblastoma at the single-cell level: Recent advances and future challenges.
Yabo YA; Heiland DH
PLoS Biol; 2024 May; 22(5):e3002640. PubMed ID: 38814900
[TBL] [Abstract][Full Text] [Related]
3. Emerging Therapies for Glioblastoma.
Rios SA; Oyervides S; Uribe D; Reyes AM; Fanniel V; Vazquez J; Keniry M
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672566
[TBL] [Abstract][Full Text] [Related]
4. Principles in the Management of Glioblastoma.
Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
[TBL] [Abstract][Full Text] [Related]
5. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
6. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
[TBL] [Abstract][Full Text] [Related]
7. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma.
Wirsching HG; Galanis E; Weller M
Handb Clin Neurol; 2016; 134():381-97. PubMed ID: 26948367
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers investigated in glioblastoma.
Tabouret E; Chinot O; Sanson M; Loundou A; Hoang-Xuan K; Delattre JY; Idbaih A
Expert Rev Mol Diagn; 2014 Sep; 14(7):883-93. PubMed ID: 25096963
[TBL] [Abstract][Full Text] [Related]
10. NCCN CNS tumor guidelines update for 2023.
Nabors B; Portnow J; Hattangadi-Gluth J; Horbinski C
Neuro Oncol; 2023 Dec; 25(12):2114-2116. PubMed ID: 37706665
[No Abstract] [Full Text] [Related]
11. The Current Landscape of Glioblastoma Biomarkers in Body Fluids.
Zanganeh S; Abbasgholinejad E; Doroudian M; Esmaelizad N; Farjadian F; Benhabbour SR
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568620
[TBL] [Abstract][Full Text] [Related]
12. Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status.
Lessi F; Morelli M; Franceschi S; Aretini P; Menicagli M; Marranci A; Pasqualetti F; Gambacciani C; Pieri F; Grimod G; Zucchi V; Cupini S; Di Stefano AL; Santonocito OS; Mazzanti CM
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373295
[TBL] [Abstract][Full Text] [Related]
13. Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven Approach.
Barzegar Behrooz A; Latifi-Navid H; da Silva Rosa SC; Swiat M; Wiechec E; Vitorino C; Vitorino R; Jamalpoor Z; Ghavami S
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370767
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
